Erwinia asparaginase should be used for the second- or third-line treatment of acute lymphoblastic leukaemia (ALL), depending upon regulatory requirements, in patients developing hypersensitivity to E. coli asparaginase preparations [83]. Here, ASPG is linked to acute lymphoblastic leukemia.